HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

MEDICA 16

Also Known As:

3,3,14,14-tetramethylhexanedecanedioic acid; MEDIC-16

Networked: 7 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Lipids: 114793
- Fatty Acids: 27405
  - Palmitic Acids: 35
    - MEDICA 16: 7

Experts

1.	Casas, Josefina: 1 article (01/2016)
2.	Martín-Acebes, Miguel A: 1 article (01/2016)
3.	Merino-Ramos, Teresa: 1 article (01/2016)
4.	Saiz, Juan-Carlos: 1 article (01/2016)
5.	Sobrino, Francisco: 1 article (01/2016)
6.	Vázquez-Calvo, Ángela: 1 article (01/2016)

Related Diseases

1.	Obesity 12/01/1988 - "The overall effect of MEDICA 16 in sand rats may reflect the pharmacological potential of MEDICA compounds in pathological hyperlipidemic-obesity-diabetic syndromes." 10/01/1999 - "In other rodent strains, MEDICA 16 has prevented obesity diabetes and atherogenesis. " 07/01/1995 - "We conclude that long-term (33 weeks) MEDICA 16 treatment of an animal model for the obesity/insulin-resistant/hyperlipidemic syndrome not only markedly improved lipid metabolism, but also inhibited the development of advanced cardiovascular disease." 12/01/1997 - "In conclusion, MEDICA 16 treatment results in the sensitization of liver, muscle, and adipose tissue to insulin in an animal model for obesity-induced insulin resistance."
2.	Cardiovascular Diseases (Cardiovascular Disease) 07/01/1995 - "We conclude that long-term (33 weeks) MEDICA 16 treatment of an animal model for the obesity/insulin-resistant/hyperlipidemic syndrome not only markedly improved lipid metabolism, but also inhibited the development of advanced cardiovascular disease."
3.	Atherosclerosis 10/01/1999 - "In other rodent strains, MEDICA 16 has prevented obesity diabetes and atherogenesis. " 07/01/1995 - "Inhibition of atherosclerosis and myocardial lesions in the JCR:LA-cp rat by beta, beta'-tetramethylhexadecanedioic acid (MEDICA 16)." 07/01/1995 - "Atherosclerosis-prone, insulin-resistant JCR:LA-cp male rats were treated from 6 weeks to 39 weeks of age with beta,beta'-tetramethylhexadecanedioic acid (MEDICA 16). "
4.	Insulin Resistance 05/01/1998 - "Development of insulin resistance in the JCR:LA-cp rat: role of triacylglycerols and effects of MEDICA 16." 12/01/1997 - "In conclusion, MEDICA 16 treatment results in the sensitization of liver, muscle, and adipose tissue to insulin in an animal model for obesity-induced insulin resistance." 12/01/1997 - "Beta,beta'-methyl-substituted hexadecanedioic acid (MEDICA 16) consists of a nonmetabolizable long-chain fatty acid designed to probe the effect exerted by fatty acids on insulin sensitivity. " 05/01/1998 - "Treatment with the potent triacylglycerol-lowering agent MEDICA 16 (beta,beta'-tetramethylhexadecanedioic acid) from 6 weeks of age reduces plasma lipids markedly, but it reduces body weight and insulin resistance only modestly. "
5.	West Nile Fever 01/01/2016 - "Furthermore, treatment with another ACC inhibitor, 3,3,14,14-tetramethylhexadecanedioic acid (MEDICA 16), also inhibited WNV infection. "

Related Drugs and Biologics

1.	Insulin (Novolin)
2.	Acids
3.	Triglycerides (Triacylglycerol)
4.	Lipids
5.	Fatty Acids (Saturated Fatty Acids)
6.	hexadecanedioic acid